Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952267 | 0.87 | CHRM2 (0.65) | POLBCHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL3996281 | 0.82 | CHRM2 (0.66) | POLBCHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL3997295 | 0.81 | SIGMAR1 (0.62) | POLBCHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL3997077 | 0.80 | SIGMAR1 (0.61) | CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL3995763 | 0.80 | SIGMAR1 (0.67) | CHRM2CHRM1CHRM3SIGMAR1DRD4 | |
| SCHEMBL3996386 | 0.78 | CHRM2 (0.63) | POLBCHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL13003260 | 0.78 | SIGMAR1 (0.68) | POLBCHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL3306841 | 0.78 | SIGMAR1 (0.68) | POLBSIGMAR1KMT2AALDH1A1DRD4 | |
| SCHEMBL2425554 | 0.76 | SIGMAR1 (0.78) | POLBSIGMAR1KMT2ADRD4DRD2 | |
| SCHEMBL17294676 | 0.76 | CHRM3 (0.72) | CHRM2CHRM1CHRM3SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066619-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | claimed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | claimed |
| EP-2066619-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | POLB 2011/4885CHRM2 3602/4885CHRM1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.